Division of Sotera Health LLC
Latest From Nordion Inc.
August was another slow month for announcements of medical device approvals outside the US, but the short list of non-US approvals this month includes a broad range of device-types approved, notably a much-awaited expanded indication for Medtronic’s CoreValve Evolut R, in six different territories.
UK-listed BTG PLC is on a route to a major future in interventional medicine, having built solid foundations in licensing and specialty pharma. CEO Louise Makin describes the deal- and decision-making rationale that has allowed a mid-cap player to set billion-dollar plus ambitions in interventional medicine, based on organic and M&A growth.
The specialist-focused health care company is building a multi-asset interventional medicines business, including multiple drug-device combination products, which it expects will grow from $150 million in annual sales to more than $1 billion by fiscal 2021.
The specialist health care company is building a multi-asset interventional medicines business that it expects will grow from $150 million in annual sales to more than $1 billion by fiscal 2021.
- Diagnostic Imaging Equipment & Supplies
- Infection Control-Sterilization
- Radiopharmaceuticals, Contrast Agents
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Neurology, Nervous System
- MDS Inc.
- North America
- Parent & Subsidiaries
- Sotera Health LLC
- Senior Management
Steve M West, CEO
Peter Dans, CFO
- Contact Info
Phone: (613) 592-2790
447 March Rd.
Ottawa, K2K 1X8
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.